| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Glass House Brands Inc.
$7.94
+0.01 (+0.13%)
Market Cap
714.26 M
EPS
-
P/E Ratio
-
Value Trade
3.30 M
-4.69 %
Week
-17.78 %
1 Month
-38.71 %
3 Month
-38.71 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
240.70 K
52 Week Range
-
% held by Insiders
13.23 %
% held by Institutions
24.86 %
Enterprise Value
-
Total Shares
90.30 M
Short %
0.27 %
Float Shares
68.13 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Glass House Brands Inc.
28Total events
4Upcoming
2Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
▲Manufacturing MilestoneCMC / Inspection
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GLAS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GLAS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-GLAS
Sep 14, 2026▲ +0.1%today
Glass House Brands Releases Mama Sue Professional Athlete Balm for Sale in California
Glass House Brands has launched the Mama Sue Professional Athlete Balm, its first topical product, in California. This balm utilizes proprietary transdermal technology and is designed for quick absorption and effective pain relief. Developed in collaboration with professional athletes, it aims to address everyday aches and pains. The product is now available at select licensed dispensaries.
Read more →-GLAS
Sep 4, 2026Glass House Brands to Participate in Upcoming September Investor Conferences
Glass House Brands Inc. announced its participation in several upcoming investor conferences in September 2026. The conferences include the ATB Cormark Capital Markets Life Sciences Fall Institutional Investor Conference, Lake Street Capital Markets Best Ideas Growth Conference, and H.C. Wainwright Global Investment Conference. Management will host one-on-one meetings with investors at these events to discuss the company's growth and strategies.
Read more →-GLAS
Aug 13, 2026▼ -5.6%on this news
Glass House Brands Reports Second Quarter 2026 Financial Results
Glass House Brands reported its second quarter 2026 financial results, highlighting record biomass production of 246,000 pounds and a cost of production of $122 per pound. The company has completed the deconsolidation of its retail operations and uplisted to the NYSE. Despite a slight decrease in revenue compared to the previous year, adjusted EBITDA turned positive at $5.7 million.
Read more →-GLAS
Aug 10, 2026Glass House Brands to Host Second Quarter 2026 Earnings Call on August 13, 2026
Glass House Brands Inc. will report its financial results for Q2 2026 on August 13, 2026, after market close. A conference call will be held at 5:00 p.m. ET to discuss these results. The company emphasizes its growth in the cannabis market and commitment to sustainability. Participants can access the live webcast or dial in for the call.
Read more →-GLAS
Jul 27, 2026Glass House Brands Retains Former DEA Compliance Executive to Advise on Interstate Commerce and Export Opportunities
Glass House Brands has appointed Matt Murphy, a former DEA compliance executive, as an advisor to enhance its regulatory compliance for interstate commerce and medical cannabis exports. Murphy's expertise will help the company navigate the complexities of the Controlled Substances Act. The initiative aims to facilitate the secure distribution of cannabis products beyond California, targeting international markets.
Read more →-GLAS
Jul 15, 2026Glass House Brands Announces the Filing of an Updated At-The-Market Distribution Program
Glass House Brands Inc. has announced an update to its at-the-market distribution program, allowing the sale of up to $100 million in equity shares. This update enables sales in the U.S. following the company's recent NYSE listing. Proceeds from the program are intended for cultivation expansion and potential acquisitions, although market conditions may affect actual sales.
Read more →-GLAS
Jul 7, 2026Glass House Brands Completes First International Hemp Sale
Glass House Brands has completed its first international sale of smokeable CBD biomass to Europe, marking a significant milestone for the company. The product originates from the initial harvest of Greenhouse 4 at their Camarillo Farm, which is compliant with California regulations. The company aims to leverage this initial sale for future product development and expansion into the European market.
Read more →Competitive Position
How GLAS ranks across every disease it competes inCompetitive Position is a premium feature
See how GLAS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial